ArticlemBio2025
mGem: Immune recognition and clearance of bacteriophages-implications for phage therapy.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Revisiting the Fight AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Phage-Based Approaches to ChronicAntibiotics (Basel, Switzerland) · 2026Review
- When bacteriophages encounter macrophages during their journey through the human body.Frontiers in cellular and infection microbiology · 2026Review
- Harnessing phages in the age of antibiotic resistance: immunological perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages (phages) hold significant promise as targeted antibacterial therapies in the era of rising multidrug-resistant infections. Despite their therapeutic potential, the clinical application of phages for human infections has been significantly hindered by the rapid and robust immune response to phages in blood. The rapid clearance of >99% of phages from circulation within hours of injection is the result of innate and adaptive immune responses that target therapeutic phage for clearance and destruction. Methodologies must be developed to isolate and/or modify phages that are not only therapeutically potent but also immunologically camouflaged. The resulting second- and third-generation phage therapies will be more effective by evading host immune responses, enabling more efficient targeting of bacterial pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.